Loading...
Under maintenance — back shortly
Anti-inflammatory→pulmonary vascular remodeling suppression
Atorvastatin may suppress pulmonary vascular remodeling in COPD through anti-inflammatory and anti-proliferative effects on vascular smooth muscle cells, reducing pulmonary hypertension progression; a preclinical rat study provides mechanistic support. This is not an approved indication and represents a novel repurposing opportunity.
“Effects of atorvastatin in suppressing pulmonary vascular remodeling in rats with chronic obstructive pulmonary disease.”
— Effects of atorvastatin in suppressing pulmonary vascular remodeling in rats with chronic obstructive pulmonary disease. (2023)DOI“Tongxinluo enhances the effect of atorvastatin on the treatment of atherosclerosis with chronic obstructive pulmonary disease by maintaining the pulmonary microvascular barrier.”
— Tongxinluo enhances the effect of atorvastatin on the treatment of atherosclerosis with chronic obstructive pulmonary disease by maintaining the pulmonary microvascular barrier. (2022)DOI“This drug is recommended for treatment of patients suffering from chronic-obstructive-pulmonary-disease with chronic-bronchitis.”
— Validated HPLC Method for Assay and Content Uniformity Testing of Roflumilast in Blend and Tablets (2020)DOI